Список литературы

61. Dougherty M.J., Santi M., Brose M.S., Ma C., Resnick A.C., Sievert A.J., et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Оncol 2010;12(7):621–30. DOI: 10.1093/neuonc/noq007

62. Schindler G., Capper D., Meyer J., Janzarik W., Omran H., Herold-Mende C., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta neuropathol 2011;121(3):397–405. DOI: 10.1007/s00401-011-0802-6

63. Chi A.S., Batchelor T.T., Yang D., Dias-Santagata D., Borger D.R., Ellisen L.W., et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013;31(14):e233–6. DOI: 10.1200/JCO.2012.46.0220

64. Migliorini D., Aguiar D., Vargas M.-I., Lobrinus A., Dietrich P.-Y. BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma. Neurol 2017;88(13):1291–3. DOI: 10.1212/WNL.0000000000003767

65. Reni M., Brandes A.A., Vavassori V., Cavallo G., Casagrande F., et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004;100(6):1221–9. DOI: 10.1002/cncr.20074

66. Quant, E.C., Wen, P.Y. Response Assessment in Neuro-Oncology. Curr Oncol Rep 2010;13(1):50–6.

67. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649−55.

68. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. (ed.). Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949:191–205.

69. Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S240–52.

70. Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn , Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven, Pim French , Monika E Hegi, Asgeir S Jakola, Michael Platten, Patrick Roth, Roberta Rudà, Susan Short, Marion Smits, Martin J B Taphoorn, Andreas von Deimling, Manfred Westphal, Riccardo Soffietti, Guido Reifenberger, Wolfgang Wick. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.

71. RUSSCO, Рекомендации по поддерживающей и сопроводительной терапии. ‒ 2024. – URL: https://rosoncoweb.ru/standarts/RUSSCO/2024/2024-1_1-10.pdf

72. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Central Nervous System Cancers. ‒ 2024. – URL: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.https://www.nccn.org/patients/guidelines/content/PDF/brain-gliomas-patient.pdf

73. Онкопсихология для врачей-онкологов и медицинских психологов. / А.М.Беляев, В.А.Чулкова, Т.Ю.Семиглазова, М.В.Рогачев. – Санкт Питербург: Ассоциация онкологов Северо-Западного федерального округа, 2017. – 352 c.

74. Fors MM, Viada CE, Gonzalez P. Use of Recursive Partitioning Analysis in Clinical Trials and Meta-Analysis of Randomized Clinical Trials, 1990-2016. Rev Recent Clin Trials. 2017;12(1):3-7. doi: 10.2174/1574887111666160916144658. PMID: 27633964.

75. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963. PMID: 16735709.

76. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007 Aug 1;25(22):3357-61. doi: 10.1200/JCO.2007.10.7722. PMID: 17664483.

77. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601.

78. Manuel Diezi, Barry Pizer, Matthew J. Murray, Overview of current European practice for the management of patients with intracranial germ cell tumours, EJC Paediatric Oncology, Volume 3, 2024, 100146, ISSN 2772-610X, https://doi.org/10.1016/j.ejcped.2024

79. Нейрохирургия. Национальное руководство. Том IV. Нейроонкология/ Под ред. А.Н.Коновалова, Д.Ю.Усачева, Д.И.Пицхелаури, В.Н.Шимансковго, В.А.Черекаева, П.Л.Калинина, А.В.Голанова. - ФГАУ "Национальный миедицинский исследовательский центр нейрохирургии имени академика Н.Н.Бурденко" Министерства здравоохранения РФ, 2025 - стр. 432: ил.

80. Zoto Mustafayev T, Turna M, Bolukbasi Y, Tezcanli E, Guney Y, Dincbas FO, Atasoy BM, Ugurluer G, Caglar HB, Atalar B, Ozyar E. Clinical and radiological effects of Bevacizumab for the treatment of radionecrosis after stereotactic brain radiotherapy. BMC Cancer. 2024 Jul 30;24(1):918. doi: 10.1186/s12885-024-12643-6

81. Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320

82.Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164

83. Takei J, Fukasawa N, Tanaka T, Yamamoto Y, Tamura R, Sasaki H, Akasaki Y, Kamata Y, Murahashi M, Shimoda M, Murayama Y. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas. Front Oncol. 2022 Jun 17;12:898614.

84. Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. PMID: 26847813.

85. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. PMID: 18772354; PMCID: PMC2718961.

86. Mrugala MM, Crew LK, Fink JR, Spence AM. Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett. 2012 Nov;4(5):1082-1086. doi: 10.3892/ol.2012.839. Epub 2012 Aug 1. PMID: 23162656; PMCID: PMC3499591

87. van der Meulen M, Chahal M, Mason WP. The Value of Etoposide for Recurrent Glioma. Can J Neurol Sci. 2024 Jul;51(4):509-512. doi: 10.1017/cjn.2023.276

88. Leonardo Rojas et al. Profiling response to carmustine/bevacizumab in recurrent glioblastoma. JCO 34, 2059-2059(2016). DOI:10.1200/JCO.2016.34.15_suppl.2059

89. Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, Ramón JF, Useche N, Bermúdez S, Pineda D, Cifuentes H, Rojas L, Ricaurte L, Pino LE, Balaña C, Arrieta O. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS One. 2019 Jun 20;14(6):e0217340. doi: 10.1371/journal.pone.0217340

90. Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010 May;97(3):389-92. doi: 10.1007/s11060-009-0032-0. Epub 2009 Oct 20. PMID: 19841864.

91. Li, Q., Wu, G., Sun, Z. et al. Temozolomide plus rituximab for elderly with relapsed primary central nervous system lymphoma. Chin. -Ger. J. Clin. Oncol. 10, 415–417 (2011). https://doi.org/10.1007/s10330-011-0803-x